Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pregabalin 1-Year Safety Extension in Anxiety Disorders
NCT00150449Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2001
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of pregabalin in generalized anxiety disorder (GAD), Social Anxiety Disorder (SAD), panic disorder, sponsored by Pfizer. Started Jan 2001; status: completed.
02
Drugs
pregabalin
03
Conditions
generalized anxiety disorder (GAD)Social Anxiety Disorder (SAD)panic disorder
Beyond the preview
Go deeper on NCT00150449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00150449.